Nampt-IN-1
- Product Name
- Nampt-IN-1
- CAS No.
- 1698878-14-6
- Chemical Name
- Nampt-IN-1
- Synonyms
- LSN3154567;Nampt-IN-1;Nampt inhibitor 1;LSN3154567 (Nampt-IN-1);LSN 3154567 (LSN-3154567;Nampt-IN-1, 10 mM in DMSO;LSN 3154567;LSN-3154567;LSN3154567;2-hydroxy-2-methyl-N-[1,2,3,4-tetrahydro-2-[2-(3-pyridinyloxy)acetyl]-6-;2-Hydroxy-2-methyl-N-[1,2,3,4-tetrahydro-2-[2-(3-pyridinyloxy)acetyl]-6-isoquinolinyl]-1-propanesulfonamide;2-hydroxy-2-methyl-N-(2-(2-(pyridin-3-yloxy)acetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)propane-1-sulfonamide
- CBNumber
- CB53048664
- Molecular Formula
- C20H25N3O5S
- Formula Weight
- 419.49
- MOL File
- 1698878-14-6.mol
Nampt-IN-1 Property
- Boiling point:
- 659.9±65.0 °C(Predicted)
- Density
- 1.363±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- DMSO: Soluble
- form
- powder
- pka
- 8.67±0.20(Predicted)
- color
- white to beige
- InChI
- 1S/C20H25N3O5S/c1-20(2,25)14-29(26,27)22-17-6-5-16-12-23(9-7-15(16)10-17)19(24)13-28-18-4-3-8-21-11-18/h3-6,8,10-11,22,25H,7,9,12-14H2,1-2H3
- InChIKey
- QHHSCLARESIWBH-UHFFFAOYSA-N
- SMILES
- [S](=O)(=O)(Nc1cc2c(cc1)CN(CC2)C(=O)COc3cnccc3)CC(O)(C)C
Safety
- WGK Germany
- WGK 3
- Storage Class
- 11 - Combustible Solids
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- SML2249
- Product name
- LSN3154567
- Purity
- ≥98% (HPLC)
- Packaging
- 25mg
- Price
- $404
- Updated
- 2026/03/19
- Product number
- SML2249
- Product name
- LSN3154567
- Purity
- ≥98% (HPLC)
- Packaging
- 5mg
- Price
- $88.64
- Updated
- 2025/07/31
- Product number
- 26066
- Product name
- Nampt-IN-1
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $44
- Updated
- 2024/03/01
- Product number
- 26066
- Product name
- Nampt-IN-1
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $172
- Updated
- 2024/03/01
- Product number
- 26066
- Product name
- Nampt-IN-1
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $321
- Updated
- 2024/03/01
Nampt-IN-1 Chemical Properties,Usage,Production
Description
Nampt-IN-1 is a potent inhibitor of nicotinamide phosphoribosyltransferase (Nampt; IC50 = 3.1 nM). It is selective for Nampt over a panel of greater than 100 human kinases at 1 μM. Nampt-IN-1 inhibits NAD+ formation in and proliferation of HCT116 cells (IC50s = 1.8 and 8.9 nM, respectively). It inhibits cell growth in a panel of cancer cell lines (IC50s = <0.2-2 μM). Nampt-IN-1 inhibits NAD+ formation in an A2780 ovarian carcinoma mouse xenograft model (ED50 = 2 mg/kg).
Uses
Nampt-IN-1 functions as a co-drug. Nampt-IN-1 is a potent and selective NAMPT inhibitor.
Biochem/physiol Actions
LSN3154567 might be useful in developing a novel cancer therapeutic.
in vivo
Nampt-IN-1 (LSN3154567) exhibits good physical chemical properties that allow oral dosing. When dosed orally with 2 mg/kg in mice, it has an exposure of 195 nM*hour in the plasma with a peak concentration of 57 nM (at 0.25 hour) and an oral bioavailability of 39%. When dosed intravenously with 2 mg/kg, it has a hepatic clearance of 158.73 mL/min/kg and a volume of distribution at 7.1 L/kg. The half-life of terminal elimination is estimated to be 2.76 hours. LSN3154567 exhibits a dose-dependent inhibition of NAD+ formation with estimated TED50 value of 2.0 mg/kg. To assess whether LSN3154567 causes retinopathy, rats are treated with LSN3154567 at 20, 40, and 80 mg/kg for 4 days. No apparent retinopathy is observed. The hematological toxicities are observed. When LSN3154567 is dosed at 20, 40, and 80 mg/kg, the plasma exposures obtained are 8,974, 18,061, and 38,327 M*h, respectively. Thus, LSN3154567 exhibits exposure multiples of respective 3-, 7-, and 14-fold over the exposure (2,701 M*h) required for robust efficacy (≈103%) without NA coadministration. Dogs are treated with LSN3154567 at 1 and 2.5 mg/kg. At these dose levels, the retinal toxicity is observed. Degeneration of the outer nuclear layer occurred in all four animals, but is less pronounced in the animals treated with 1 mg/kg. At the 1 and 2.5 mg/kg dose levels, the plasma exposures are determined to be 1,483 and 2,468 nM*h, respectively[1].
References
[1] GENSHI ZHAO. Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.[J]. Molecular Cancer Therapeutics, 2017, 16 12: 2677-2688. DOI: 10.1158/1535-7163.mct-16-0674
Nampt-IN-1 Preparation Products And Raw materials
Raw materials
Preparation Products
Nampt-IN-1 Suppliers
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
- Tel
- 021-58950125
- Fax
- (86) 21-58955996
- info@chemexpress.com
- Country
- China
- ProdList
- 7552
- Advantage
- 61
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4817
- Advantage
- 55
- Tel
- 021-61350663 13052117465
- Fax
- 021-61350662
- sales@zehanbiopharma.com
- Country
- China
- ProdList
- 979
- Advantage
- 55
- Tel
- 526763801 13301653310
- Fax
- +86-21-51619052
- 526763801@qq.com
- Country
- China
- ProdList
- 9433
- Advantage
- 55
- Tel
- 020-61288194 61288195
- Fax
- 020-61288700
- 505721671@qq.com
- Country
- China
- ProdList
- 3866
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 86249
- Advantage
- 60
- Tel
- 18930833303 18930833303
- Fax
- +86 (21) 2024-2659
- sales@changyanchem.cn
- Country
- China
- ProdList
- 5001
- Advantage
- 55
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 021-QQ：65489617 15618227136
- Fax
- 21-5161 9052
- Sales@ATKchemical.com
- Country
- China
- ProdList
- 9505
- Advantage
- 58